IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma

This study offers a preclinical proofof conceptfor development of a novel therapy that targets one of the most relevant tumor antigensin cutaneous T-cell lymphoma, where there remains unmet medical need.